



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

## AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC

The SARS-CoV-2 B.1.617.2 Delta variant of concern (VOC) continues to drive a sharp increase in COVID-19 cases in the UK, with a current doubling time of 3.5–16 days,<sup>1</sup> consistent with previous pandemic waves during 2020–21, and a sustained increase in the reproduction number (R) to 1.2–1.4.<sup>2</sup> Daily hospital admissions and the number of patients requiring mechanical ventilation are now increasing in both England and Scotland, despite the ongoing roll-out of widespread vaccination in the UK.<sup>1</sup>

The ChAdOx1 nCoV-19 (AZD1222, Oxford–AstraZeneca) vaccine forms the core of the UK's vaccination programme and the global COVAXX programme. To determine B.1.617.2 sensitivity to AZD1222-induced neutralising antibodies (NABs) and to compare this to our previous measurements of NABs induced by BNT162b2 (Pfizer–BioNTech),<sup>3</sup> we carried out a second initial analysis of Legacy study participants vaccinated with AZD1222. Legacy was initiated in early 2021 by University College London Hospitals and the Francis Crick Institute in London, UK, to track serological responses to vaccination during the national COVID-19 vaccination programme in prospectively recruited healthy staff volunteers. A description of the methods and clinical cohort are available in the appendix. The Legacy study was approved by the London Camden and Kings Cross Health Research Authority Research and Ethics committee (IRAS number 286469) and is sponsored by University College London Hospitals.

Using a high-throughput live-virus SARS-CoV-2 neutralisation assay, we determined Nab titres (NABTs) against five SARS-CoV-2 strains in 106 participants (median age 34 years, IQR 29–42) after either one dose of

AZD1222 (n=50, median time after first dose 41 days [IQR 30–51]) or two doses of AZD1222 (n=63, median time after second dose 31 days [IQR 19.5–46.0]; appendix p 7). The median interval between doses was 63 days (IQR 62.0–69.5). Consistent with our previous findings,<sup>3</sup> we included a strain with the original spike sequence (Wildtype), a strain with an Asp614Gly mutation isolated during the first wave of infection in the UK, in 2020 (D614G), and VOCs B.1.1.7 (Alpha, first detected in Kent, England), B.1.351 (Beta, first detected in South Africa), and B.1.617.2 (Delta, first detected in India).

Two doses of AZD1222 generated NAB activity against the Wildtype strain bearing a spike identical to that encoded by the vaccine in all participants (median NABT IC<sub>50</sub>=419), with a 2.1-fold (95% CI 2.0–2.2) reduction in median NABT relative to two doses of BNT162b2 (appendix p 2). Moreover, median NABTs against all SARS-CoV-2 variants were further reduced relative to BNT162b2: 2.4-fold (95% CI 2.3–2.6) against D614G, 2.4-fold against B.1.1.7 (2.2–2.5), 2.5-fold (1.3–2.8) against B.1.351, and 2.5-fold (1.4–2.7) against B.1.617.2. Given the low responses against the latter two VOCs, we found that stratification of NABTs into three groups (IC<sub>50</sub> low [ $<40$ ], medium [40–256], high [ $>256$ ]) was most illustrative: whereas nearly all participants had a quantifiable NABT against the D614G and B.1.1.7 variants (55 [87%] of 63 [95% CI 76–94%]; appendix p 2), significantly fewer participants had quantifiable NABTs against B.1.351 and B.1.617.2 VOCs after two doses of AZD1222 (38 [60%] of 63 [95% CI 47–72%] against B.1.351; and 39 [62%] of 63 [49–74%] against B.1.617.2), relative to the former two variants ( $\chi^2$  test  $p<0.0011$ ). This contrasts strongly with our previous results, which showed that more than 95% of participants had quantifiable NABTs against B.1.351 and B.1.617.2 after two doses of BNT162b2 (189 [97%] of 195 against B.1.351; and

186 [95%] of 195 against B.1.617.2). Analysis of these data by ordered logistic regression confirmed vaccine type was associated with decreased NABTs, independent of SARS-CoV-2 strain, in two-dose vaccine recipients ( $p=0.0017$ ; appendix p 4).

A single dose of AZD1222 generated a broad range of NAB activity against Wildtype SARS-CoV-2 (appendix p 2). Given reports of enhanced NAB responses to VOCs B.1.1.7 and B.1.351 after a single dose of mRNA vaccines in individuals with previous SARS-CoV-2 infection,<sup>4,5</sup> in the absence of concrete evidence of previous infection, we stratified NABT by whether participants reported prior COVID-19 symptoms and found markedly different responses. After a single AZD1222 dose, participants with prior COVID-19 symptoms (16 [32%] of 50) had significantly higher NABTs against all strains than those without prior COVID symptoms ( $5.1 \times 10^{-5} \leq p \leq 3.1 \times 10^{-4}$ ). Since many responses fell outside of the quantitative limit of detection, stratification of NABTs was again informative. Whereas participants without prior COVID-19 symptoms mostly had quantifiable NABTs against Wildtype (31 [91%] of 34 [95% CI 75–98%]), significantly more NAB responses against VOCs were below the limit of detection: 22 [65%] of 34 [95% CI 46–80%]) against B.1.1.7; 30 [88%] of 34 [72–96%]) against B.1.351; and 29 [85%] of 34 [68–94%]) against B.1.617.2 ( $2.8 \times 10^{-10} \leq p \leq 6.0 \times 10^{-6}$ ; appendix p 2). Analysis by ordered logistic regression confirmed that a previous history of COVID-19 symptoms was associated with increased NABTs, independent of SARS-CoV-2 strain, in single-dose AZD1222 recipients ( $p=0.0016$ ; appendix p 4).

These data, together with our previous findings,<sup>3</sup> reveal that AZD1222 recipients have lower NABTs than BNT162b2 recipients against SARS-CoV-2 variants, including B.1.617.2 (appendix p 3). This finding is in line with the vaccine-induced



Barcroft/Medical/Getty Images

Published Online  
June 28, 2021  
[https://doi.org/10.1016/S0140-6736\(21\)01462-8](https://doi.org/10.1016/S0140-6736(21)01462-8)

See Online for appendix

Submissions should be made via our electronic submission system at <http://ees.elsevier.com/thelancet/>

NABTs observed during clinical trials of AZD1222<sup>6</sup> and BNT162b2.<sup>7</sup> Notably, our data are consistent with preliminary observational estimates based on rates of S gene target failure during PCR testing in England<sup>8</sup> and more recent data from Scotland,<sup>9</sup> which reports 19% reduced AZD1222 efficacy following two doses (60%) relative to two doses of BNT162b2 (79%) against the B.1.617.2 variant and similar to reduced efficacy against the B.1.1.7 variant following two doses (73% for AZD1222 vs 92% for BNT162b2). The combination of these observational data with our laboratory data suggests that the correlation between NABTs and vaccine efficacy in recent models<sup>10</sup> continues to perform well across different vaccine types and SARS-CoV-2 variants (appendix p 5). It further highlights that the lower starting NABTs of AZD1222 recipients will now render vaccine efficacy more susceptible to any possible individual-level variation (eg, prior infection, age, immune status, antibody durability, comorbidities). Prevention of infection, however, appears to require substantially higher NABTs than prevention of the most severe COVID-19 disease and death. Therefore, although reduced in-vitro neutralisation of VOCs predicts reduced AZD1222 vaccine efficacy against symptomatic infection with the same VOCs, close monitoring of the unfolding pandemic will reveal the extent to which the link with severe or fatal COVID-19 has been broken by all current vaccines.

Given our previous observation of decreased NABTs in older BNT162b2 recipients,<sup>3</sup> we note that our observation here of lower median NABTs of about 2.5-fold in two-dose AZD1222 recipients relative to two-dose BNT162b2 recipients is confounded by the fact that the AZD1222 cohort is significantly younger than the BNT162b2 cohort (median age 33 years [IQR 28–41] vs 42 years [33–52],  $p=2.3 \times 10^{-8}$ ); comparison of two-dose AZD1222 recipients to a more similar subset of the two-dose BNT162b2 cohort ( $n=58$ , single study site, age <50 years, dosing interval >40 days; appendix p 4), shows

a more pronounced reduction in median NABTs against B.1.617.2 between two-dose AZD1222 and two-dose BNT162b2 recipients (appendix p 5). Along with increased standardisation across serological laboratories, further serological examination of AZD1222 recipients will be needed as the UK vaccination programme continues, to assess the extent to which variables such as age affect NABTs (especially beyond the median 31 days post-second dose examined here) and vaccine efficacy, and to establish and refine correlates of protection against all SARS-CoV-2 variants.

Our data reinforce the need to recognise the increased protection offered by a second vaccine dose as COVID-19 cases associated with the B.1.617.2 variant increase. They also suggest that further booster immunisations might be needed, especially for more susceptible groups that have received vaccines that induce lower than average NABTs. As with mRNA vaccines, it might be feasible to prioritise the use of the AZD1222 vaccine, in light of severely restricted supply, for people with a confirmed history of COVID-19. Overall, our findings highlight the urgent need for expanded serological monitoring of NABTs within sub-populations. This will enable a better understanding of the evolution of vaccine efficacy and facilitate the production of updated vaccines, thereby ensuring maximum protection against SARS-CoV-2 variants.

CSw reports grants from BMS, Ono-Pharmaceuticals, BoehringerIngelheim, Roche-Ventana, Pfizer, and Archer Dx, unrelated to this Correspondence; personal fees from Genentech, Sarah Canon Research Institute, Medixi, Bicycle Therapeutics, GRAIL, Amgen, AstraZeneca, BMS, Illumina, GlaxoSmithKline, MSD, and Roche-Ventana, unrelated to this Correspondence; and stock options from Apogen Biotech, Epic Biosciences, GRAIL, and Achilles Therapeutics, unrelated to this Correspondence. All other authors declare no competing interests. ECW, MW, and RH contributed equally. GKa, CSw, SGan, and DLVB are joint senior authors. RB and DLVB are members of the Genotype-to-Phenotype UK National Virology Consortium. Funding details and acknowledgments can be found in the appendix. All data (anonymised) and full R code to produce all figures and statistical analysis presented in this Correspondence are available online on GitHub.

Emma C Wall, Mary Wu, Ruth Harvey, Gavin Kelly, Scott Warchal, Chelsea Sawyer, Rodney Daniels, Lorin Adams, Philip Hobson, Emine Hatipoglu, Yenting Ngai, Saira Hussain, Karen Ambrose, Steve Hindmarsh, Rupert Beale, Andrew Riddell, Steve Gamblin, Michael Howell, George Kassiotis, Vincenzo Libri, Bryan Williams, Charles Swanton, Sonia Gandhi, \*David LV Bauer  
david.bauer@crick.ac.uk

Francis Crick Institute, London NW1 1AT, UK (ECW, MW, RH, GKe, SW, CSa, RD, LA, PH, SHu, KA, SHi, RB, AR, SGam, MH, GKa, CSw, SGan, DLVB); National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, London, UK (ECW, VL, BW); NIHR UCLH Clinical Research Facility, London, UK (ECW, RB, VL, BW); University College London, London, UK (RB, EH, YN, VL, BW, CSw, SGan); Department of Infectious Disease, St Mary's Hospital, Imperial College London, London, UK (GKa)

- Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 16. June 18, 2021. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/994839/Variants\\_of\\_Concern\\_VOC\\_Technical\\_Briefing\\_16.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/994839/Variants_of_Concern_VOC_Technical_Briefing_16.pdf) (accessed June 24, 2021).
- Department of Health and Social Care and Scientific Advisory Group for Emergencies. The R value and growth rate. June 18, 2021. <https://www.gov.uk/guidance/the-r-value-and-growth-rate> (accessed June 24, 2021).
- Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *Lancet* 2021; **397**: 2331–33.
- Stamatatos L, Czartoski J, Wan Y-H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science* 2021; published online March 25. <https://doi.org/10.1126/science.abg9175>.
- Reynolds CJ, Pade C, Gibbons JM, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. *Science* 2021; published online April 30. <https://doi.org/10.1126/science.abh1282>.
- Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet* 2020; **396**: 467–78.
- Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses. *Nature* 2020; **586**: 594–99.
- Bernal JL, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. *MedRxiv* 2021; published online May 24. <https://doi.org/10.1101/2021.05.22.21257658> (preprint).

- 9 Sheikh A, McMenamin J, Taylor B, Robertson C, on behalf of Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* 2021; **397**: 2461–62.
- 10 Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021; published online May 17. <https://doi.org/10.1038/s41591-021-01377-8>.

## Science, not speculation, is essential to determine how SARS-CoV-2 reached humans

On Feb 19, 2020, we, a group of physicians, veterinarians, epidemiologists, virologists, biologists, ecologists, and public health experts from around the world, joined together to express solidarity with our professional colleagues in China.<sup>1</sup> Unsubstantiated allegations were being raised about the source of the COVID-19 outbreak and the integrity of our peers who were diligently working to learn more about the newly recognised virus, SARS-CoV-2, while struggling to care for the many patients admitted to hospital with severe illness in Wuhan and elsewhere in China.

It was the beginning of a global tragedy, the COVID-19 pandemic. According to WHO, as of July 2, 2021, the pandemic has resulted in 182 101 209 confirmed cases and 3 950 876 deaths, both undoubtedly underestimates of the real toll. The impact of the pandemic virtually everywhere in the world has been far worse than even these numbers suggest, with unprecedented additional social, cultural, political, and economic consequences that have exposed numerous flaws in our epidemic and pandemic preparedness and in local and global political and economic systems. We have observed escalations of conflicts that pit many parties against one another, including central government versus local

government, young versus old, rich versus poor, people of colour versus white people, and health priorities versus the economy. The crisis has highlighted the urgent need to build a better understanding of how science proceeds and the complex, but critical, links science has with health, public health, and politics.

Recently, many of us have individually received inquiries asking whether we still support what we said in early 2020.<sup>1</sup> The answer is clear: we reaffirm our expression of solidarity with those in China who confronted the outbreak then, and the many health professionals around the world who have since worked to exhaustion, and at personal risk, in the relentless and continuing battle against this virus. Our respect and gratitude have only grown with time.

The second intent of our original Correspondence was to express our working view that SARS-CoV-2 most likely originated in nature and not in a laboratory, on the basis of early genetic analysis of the new virus and well established evidence from previous emerging infectious diseases, including the coronaviruses that cause the common cold as well as the original SARS-CoV and MERS-CoV.<sup>2</sup> Opinions, however, are neither data nor conclusions. Evidence obtained using the scientific method must inform our understanding and be the basis for interpretation of the available information. The process is not error-free, but it is self-correcting as good scientists endeavour to continually ask new questions, apply new methodologies as they are developed, and revise their conclusions through an open and transparent sharing of data and ongoing dialogue.

The critical question we must address now is, how did SARS-CoV-2 reach the human population? This is important because it is such insights that will drive what the world must urgently do to prevent

another tragedy like COVID-19. We believe the strongest clue from new, credible, and peer-reviewed evidence in the scientific literature<sup>3–6</sup> is that the virus evolved in nature, while suggestions of a laboratory-leak source of the pandemic remain without scientifically validated evidence that directly supports it in peer-reviewed scientific journals.<sup>7,8</sup>

Careful and transparent collection of scientific information is essential to understand how the virus has spread and to develop strategies to mitigate the ongoing impact of COVID-19, whether it occurred wholly within nature or might somehow have reached the community via an alternative route, and prevent future pandemics. Allegations and conjecture are of no help, as they do not facilitate access to information and objective assessment of the pathway from a bat virus to a human pathogen that might help to prevent a future pandemic. Recrimination has not, and will not, encourage international cooperation and collaboration.<sup>9</sup> New viruses can emerge anywhere, so maintaining transparency and cooperation between scientists everywhere provides an essential early warning system. Cutting professional links and reducing data sharing will not make us safer.

We welcome calls for scientifically rigorous investigations.<sup>10,11</sup> To accomplish this, we encourage WHO and scientific partners across the world to expeditiously move to continue and further extend their initial investigation with experts in China and the Chinese Government. WHO's report from March, 2021,<sup>12</sup> must be considered the beginning rather than the end of an inquiry, and we strongly support the G7 leaders' call for "a timely, transparent, expert-led, and science-based WHO-convened phase 2 COVID-19 origins study".<sup>13</sup> We also understand that it might take years of field and laboratory study to assemble and link the data essential to reach rational and objective



Sylvain Lefevre/Getty Images

Published Online  
July 5, 2021  
[https://doi.org/10.1016/S0140-6736\(21\)01419-7](https://doi.org/10.1016/S0140-6736(21)01419-7)